Baker Bros. Advisors acquired 1,485,397 shares for $21.2M across 10 transactions on Dec 13–16, raising stake 17.5% to 10.0M shares.
Baker Bros. Advisors LP, a Director, executed 10 separate open-market purchases totaling 1,485,397 shares for $21,230,384.81 at a blended average price of $14.29 on December 13–16, 2024. The acquisition increased holdings by 17.5% from 8,509,877 to 9,995,274 shares. The transaction occurred while the stock has fallen 30.5% over 30 days and 45.0% from its 52-week high of $27.51, trading at $15.14 at filing date. Bicycle Therapeutics is unprofitable (net income of $-50,802,000.00 in the latest full year) with minimal recent quarterly revenue of $2,676,000.00, though revenue growth reached 86.5% year-over-year. Baker Bros.' cross-ticker track record shows 16 prior open-market buys with a 43.75% 90-day win rate and average 90-day return of 11.3%, providing limited affirmative evidence of timing accuracy at this particular issuer.